Sign up
Pharma Capital

CytoDyn CEO updates timeline for HIV drug, addresses share dilution concerns

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors the biotech is looking to submit the entirely of its Biologics License Application on its HIV drug leromlimab by the end of July, equating to being revenue-ready by end of 1Q 2020.

Pourhassan also addressed recent shareholder concerns over potential dilution of the stock.

 

View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.